AimedBio has
successfully secured $38 million in a Pre-IPO funding round. The round was led
by existing key investors—InterVest, DS Asset Management, Samsung Life Public
Welfare Foundation, and SMB Investment Partners. Mirae Asset Securities joined
as the sole new investor.
With the newly secured funding, AimedBio plans to accelerate the development of
its next-generation ADC pipeline and advance preparations for global clinical
trials. Following the licensing of its lead asset, AMB302, to U.S.-based
Biohaven in December 2024, the company is now focusing on the preclinical
development of the next candidates AMB303 and AMB304. At the same time, AimedBio
aims to significantly expand its pipeline through next-generation ADC platform
technologies.
Dr. Nam-Gu Her, CEO of AimedBio stated, “This Pre-IPO round closed earlier than
expected, reflecting strong confidence from our existing shareholders. Mirae
Asset Securities’ participation signals growing market confidence in AimedBio’s
vision and potential."
“Based on our successful licensing deal to date, AimedBio is projected to
achieve operating profitability for two consecutive half-years—the second half
of 2024 and the first half of 2025. This is a significant milestone, as it
demonstrates that the company has moved beyond potential to proving its ability
to generate sustainable revenue," he added.
AimedBio also noted, "Additional technology licensing deals are expected
within this year, and with the rapid expansion of our preclinical pipeline, we
are set to accelerate high-growth momentum. Through the development of globally
competitive ADC therapies, we aim to provide meaningful treatment options to
patients and continuously enhance corporate value.”
Link to full news: https://biz.chosun.com/en/en-science/2025/06/02/Z7KR2NK4EVBETKHSBHBLY7BDUE/